Suchergebnisse - "Balagula, Yevgeniy"

PubPharm (75)

61

Necrobiotic xanthogranuloma associated with immunoglobulin m paraproteinemia in a patient with Waldenström macroglobulinemia

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2011

von Balagula, Y. | Straus, D. | Pulitzer, M. | +1

62

Necrobiotic Xanthogranuloma Associated With Immunoglobulin M Paraproteinemia in a Patient With Waldenström Macroglobulinemia

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2011

von Balagula, Y. | Straus, D. | Pulitzer, M. | +1

63

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

enthalten in: Investigational new drugs | 2011

von Balagula, Y. | Wu, S. | Su, X. | +2

64

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

enthalten in: Investigational new drugs | 2011

von Balagula, Y. | Wu, S. | Su, X. | +2

65

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

enthalten in: Investigational new drugs | 2011

von Balagula, Y. | Wu, S. | Su, X. | +2

66

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors

enthalten in: International journal of dermatology | 2011

von Balagula, Y. | Garbe, C. | Myskowski, P. | +4

67

Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors

enthalten in: International journal of dermatology | 2011

von Balagula, Y. | Garbe, C. | Myskowski, P. | +4

68

Acneiform rash as a reaction to radiotherapy in a breast cancer patient

enthalten in: The journal of supportive oncology | 2010

von Balagula, Y. | Hensley, J. | Gerami, P. | +1

69

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

enthalten in: Investigational new drugs | 2010

von Balagula, Y. | Barth Huston, K. | Busam, K. | +3

70

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

enthalten in: Investigational new drugs | 2010

von Balagula, Y. | Barth Huston, K. | Busam, K. | +3